Irmina Gozalbo

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE To compare the cost consequence of biologic drugs for moderate-to-severe psoriasis from the perspective of the Spanish National Health System. METHODS We built a decision tree with a two-year time horizon. Efficacy data for biologics (etanercept, infliximab, adalimumab, ustekinumab and secukinumab) were drawn from published meta-analyses: PASI75(More)
  • 1